loading page

Chronic graft-versus-host disease secondary to donor-derived CAR-T cells treatment in children: a report of two cases and a literature review
  • +7
  • Kai Chen,
  • Hui Jiang,
  • Yifei Cheng,
  • Na Zhang,
  • Min Xia,
  • Xueli Wang,
  • Jingbo Shao,
  • Jiashi Zhu,
  • Hong Li,
  • Xiaojun Huang
Kai Chen
Children's Hospital of Shanghai
Author Profile
Hui Jiang
Children's Hospital of Shanghai
Author Profile
Yifei Cheng
Peking University People's Hospital
Author Profile
Na Zhang
Children's Hospital of Shanghai
Author Profile
Min Xia
Children's Hospital of Shanghai
Author Profile
Xueli Wang
Children's Hospital of Shanghai
Author Profile
Jingbo Shao
Children's Hospital of Shanghai
Author Profile
Jiashi Zhu
Children's Hospital of Shanghai
Author Profile
Hong Li
Children's Hospital of Shanghai
Author Profile
Xiaojun Huang
Peking University People's Hospital
Author Profile

Abstract

Donor-derived CD19-directed chimeric antigen receptor-modified T (CAR-T) cell therapy seems be effective and safe for relapsed B-ALL after allogeneic haematopoietic stem cell transplantation (allo-HSCT). We report two cases of children who received Donor-derived CAR-T cell therapy. After transfusion, the children experienced different degrees of chronic graft-versus-host disease (cGVHD). Early intervention included strengthening immunosuppressant, FAM regimen, tyrosine kinase inhibitor, and auxiliary cell therapy. Their dyspnoea and lung function were significantly improved and recovered. They did not receive the second transplant. Timely and effective intervention is crucial to improve both prognosis and quality of life.